Drug intelligence / Profile preview

cisplatin + etoposide + paclitaxel + carboplatin

Development stage
Phase 2
Lead developer
Shanghai Gynecologic Oncology Group
Modality
Small Molecules
Administration
Intravenous, Intraperitoneal
01

Overview

PEip + TCiv is a combination chemotherapy regimen primarily investigated for the treatment of advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. The regimen involves the intraperitoneal (IP) administration of cisplatin and etoposide (PEip) alongside the intravenous (IV) administration of paclitaxel and carboplatin (TCiv). This approach aims to deliver high concentrations of cytotoxic agents directly to the peritoneal cavity, where ovarian cancer typically spreads, while maintaining systemic exposure through IV delivery. Cisplatin and carboplatin are platinum-based antineoplastic agents that form DNA cross-links, etoposide is a topoisomerase II inhibitor, and paclitaxel is a microtubule-stabilizing agent.

Other names
PEip + TCivPEip/TCiv regimenintraperitoneal cisplatin and etoposide plus intravenous paclitaxel and carboplatin
02

Targets

DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on cisplatin + etoposide + paclitaxel + carboplatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + etoposide + paclitaxel + carboplatin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call